2. Academic Validation
  3. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study

Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study

  • Bioorg Med Chem. 2018 Nov 15;26(21):5596-5611. doi: 10.1016/j.bmc.2018.10.004.
Ju-Hyeon Lee 1,  Ashraf K El-Damasy 2,  Seon Hee Seo 3,  Changdev G Gadhe 4,  Ae Nim Pae 4,  Nakcheol Jeong 5,  Soon-Sun Hong 6,  Gyochang Keum 7
Affiliations

Affiliations

  • 1 Center for Neuro-Medicine, Brain Science Institute, Korea Institute of Science and Technology, Hwarangro 14-gil 5, Seongbuk-gu, Seoul 02792, Republic of Korea; Department of Chemistry, Korea University, Anam-ro 145 Seongbuk-gu, Seoul 136-701, Republic of Korea.
  • 2 Center for Neuro-Medicine, Brain Science Institute, Korea Institute of Science and Technology, Hwarangro 14-gil 5, Seongbuk-gu, Seoul 02792, Republic of Korea; Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura 35516, Egypt.
  • 3 Center for Neuro-Medicine, Brain Science Institute, Korea Institute of Science and Technology, Hwarangro 14-gil 5, Seongbuk-gu, Seoul 02792, Republic of Korea.
  • 4 Convergence Research Center for Diagnosis, Treatment and Care System of Dementia, Korea Institute of Science and Technology, Hwarangro 14-gil 5, Seongbuk-gu, Seoul 02792, Republic of Korea.
  • 5 Department of Chemistry, Korea University, Anam-ro 145 Seongbuk-gu, Seoul 136-701, Republic of Korea.
  • 6 Department of Drug Development, College of Medicine, Inha University, 3-ga, Sinheung-dong, Jung-gu, Incheon 400-712, Republic of Korea. Electronic address: hongs@inha.ac.kr.
  • 7 Center for Neuro-Medicine, Brain Science Institute, Korea Institute of Science and Technology, Hwarangro 14-gil 5, Seongbuk-gu, Seoul 02792, Republic of Korea. Electronic address: gkeum@kist.re.kr.
PMID: 30385226 DOI: 10.1016/j.bmc.2018.10.004
Abstract

Two new series of 5-subtituted and 5,6-disubstituted pyrrolo[2,3-d]pyrimidine octamides (4a-o and 6a-g) and their corresponding free amines 5a-m and 7a-g have been synthesized and biologically evaluated for their antiproliferative activity against three human Cancer cell lines. The 5,6-disubstituted octamides 6d-g as well as the amine derivative 7b have shown the best Anticancer activity with single digit micromolar GI50 values over the tested Cancer cells, and low cytotoxic effects (GI50 > 10.0 µM) against HFF-1 normal cell. A structure activity relationship (SAR) study has been established and disclosed that terminal octamide moiety at C2 as well as disubstitution with fluorobenzyl piperazines at C5 and C6 of pyrrolo[2,3-d]pyrimidine are the key structural features prerequisite for best antiproliferative activity. Moreover, the most active member 6f was tested for its antiproliferative activity over a panel of 60 Cancer cell lines at NCI, and exhibited distinct broad spectrum Anticancer activity with submicromolar GI50 and TGI values over multiple Cancer cells. Kinase profile of compound 6f over 53 oncogenic kinases at 10 µM concentration showed its highly selective inhibitory activity towards FGFR4, Tie2 and TrkA kinases. The observed activity of 6f against TrkA (IC50 = 2.25 µM), FGFR4 (IC50 = 6.71 µM) and Tie2 (IC50 = 6.84 µM) was explained by molecular docking study, which also proposed that 6f may be a type III kinase inhibitor, binding to an allosteric site rather than kinase hinge region. Overall, compound 6f may serve as a promising Anticancer lead compound that could be further optimized for development of potent Anticancer agents.

Keywords

Antiproliferative activity; FGFR4 kinase; Mannich reaction; Molecular docking; Pyrrolo[2,3-d]pyrimidine octamides; Tie2; TrKA.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z